In last trading session, Third Harmonic Bio Inc (NASDAQ:THRD) saw 0.43 million shares changing hands with its beta currently measuring 2.71. Company’s recent per share price level of $10.84 trading at -$0.04 or -0.37% at ring of the bell on the day assigns it a market valuation of $488.44M. That closing price of THRD’s stock is at a discount of -56.27% from its 52-week high price of $16.94 and is indicating a premium of 25.55% from its 52-week low price of $8.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.2 million shares which gives us an average trading volume of 193.21K if we extend that period to 3-months.
For Third Harmonic Bio Inc (THRD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.37 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Third Harmonic Bio Inc (NASDAQ:THRD) trade information
Upright in the red during last session for losing -0.37%, in the last five days THRD remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $10.84 price level, adding 8.75% to its value on the day. Third Harmonic Bio Inc’s shares saw a change of -1.19% in year-to-date performance and have moved -3.73% in past 5-day. Third Harmonic Bio Inc (NASDAQ:THRD) showed a performance of -6.71% in past 30-days. Number of shares sold short was 3.06 million shares which calculate 10.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 45.8% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -84.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -84.5% for stock’s current value.
Third Harmonic Bio Inc (THRD) estimates and forecasts
Statistics highlight that Third Harmonic Bio Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -16.74% of value to its shares in past 6 months, showing an annual growth rate of -42.31% while that of industry is 17.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Third Harmonic Bio Inc (NASDAQ:THRD)’s Major holders
Insiders are in possession of 9.05% of company’s total shares while institution are holding 92.38 percent of that, with stock having share float percentage of 101.57%. Investors also watch the number of corporate investors in a company very closely, which is 92.38% institutions for Third Harmonic Bio Inc that are currently holding shares of the company. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the top institutional holder at THRD for having 10.91 million shares of worth $141.8 million. And as of 2024-06-30, it was holding 26.8961 of the company’s outstanding shares.
The second largest institutional holder is ORBIMED ADVISORS LLC, which was holding about 5.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 14.2498 of outstanding shares, having a total worth of $75.13 million.
On the other hand, Price (T.Rowe) Small-Cap Value Fund and Price (T.Rowe) Small Cap Stock Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 846.79 shares of worth $9.18 million or 1.88% of the total outstanding shares. The later fund manager was in possession of 564.62 shares on Sep 30, 2024 , making its stake of worth around $6.12 million in the company or a holder of 1.25% of company’s stock.
